Bimagrumab

Hej nån som vet vart jag kan få tag på bimagrumab (BYM338)?


Den förbättrade insulin känsligheten m upp tilll 40% och slaktade myostatin och sågs bygga 3.85kg fettfri massa och samtidigt tappa 22.1% av sin fettmassa, det är mycket imponerande.

Jag vill ha denna, vart kan jag få tag i den? Köper ifrån Kina om jag måste!

Kortat ner studien, hela studien finns här: https://jamanetwork.com/journals/jamanet...le/2774903

Spoiler

At week 48, the bimagrumab group gained 3.6% of lean mass (1.70 kg; 80% CI, 1.14 to 2.26 kg) compared with −0.8% (−0.4 kg; 80% CI, −1.0 to 0.1 kg) in the placebo group (P < .001), and body weight decreased by 6.5% (−5.90 kg; 80% CI, −7.08 to −4.71 kg) compared with a 0.8% decrease (−0.8 kg; 80% CI, −1.9 to 0.3 kg) in the placebo group (P < .001).

Resultat för endast män

The placebo-corrected change in lean mass in patients treated with bimagrumab was greater for men (5.1%; 2.76 kg; 80% CI, 1.66 to 3.85 kg; P = .002) vs women (2.5%; 0.98 kg; 80% CI, −0.15 to 2.11 kg; P = .26).

Both myostatin knockout and sequestration by soluble ActRII improved insulin sensitivity in preclinical animal models.25,26 Insulin sensitivity improved by approximately 20% (by hyperinsulinemic-euglycemic clamp) to 40% (by intravenous glucose tolerance test) in the patients with insulin resistance treated with bimagrumab

Värt att nämna ang resultaten

The possibility exists that the lean mass gains we observed in participants who received bimagrumab were caused by fluid or water accumulation rather than muscle protein accretion. Although we did not measure total body water or muscle water content, we are unaware of any effects of bimagrumab on water balance in this study or in earlier related studies.

Concolusion

In this study, 48 weeks of exposure to bimagrumab, an antibody inhibitor of ActRII, was safe and effective for treating the excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. While antibody blockade or knockout of ActRII in animal models is accompanied by marked increases in skeletal muscle mass, this study confirms that inhibition of this receptor in human participants leads to not only increases in lean mass but profound decreases in body fat, along with improvements in glycemic control. Inhibition of ActRII may provide a novel pathway for the pharmacologic management of excess adiposity and accompanying metabolic disturbances.